Mortality associated with the use of non‐vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban

Mortality associated with the use of non‐vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban

Abstract Objective This study assesses the mortality outcomes of non‐vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with venous thromboembolism (VTE) and atrial fibrillation (AF). Methods Medical records of cancer patients receiving NOACs for VTE or AF between January 1, 2011, a...

Full description

Bibliographic Details
Main Authors: Yu‐Sheng Lin, Feng‐Che Kuan, Tze‐Fan Chao, Michael Wu, Shao‐Wei Chen, Mien‐Cheng Chen, Chang‐Ming Chung, Pao‐Hsien Chu, Gregory Y. H. Lip, Victor Chien‐Chia Wu
Format: Article
Language:English
Published: Wiley 2021-10-01
Series:Cancer Medicine
Subjects:
atrial fibrillation
cancer
non‐vitamin K antagonist oral anticoagulants
outcome
venous thromboembolism
Online Access:https://doi.org/10.1002/cam4.4241

Internet

https://doi.org/10.1002/cam4.4241

Similar Items